Emerging blood-based biomarkers for AD include markers for the hallmark pathologies (p-tau isoforms and Aβ) and markers of axonal degeneration (neurofilament light; NfL) or astrocytosis (glial fibrillary acidic protein; GFAP [12]). The gene discussed is MAPT; the disease is Alzheimer disease.